Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16544440 | 1.00 | MEN1 (0.71) | MEN1MAPTKMT2AALDH1A1CISD1 | |
| SCHEMBL5950751 | 1.00 | MEN1 (0.71) | MEN1MAPTKMT2AALDH1A1CISD1 | |
| SCHEMBL15129044 | 0.95 | MEN1 (0.66) | MEN1MAPTKMT2AALDH1A1CISD1 | |
| SCHEMBL15129043 | 0.95 | MEN1 (0.66) | MEN1MAPTKMT2AALDH1A1CISD1 | |
| SCHEMBL11941273 | 0.95 | MEN1 (0.66) | MEN1MAPTKMT2AALDH1A1CISD1 | |
| SCHEMBL9820289 | 0.90 | CISD1 (0.65) | ALDH1A1CISD1KDM4ESLC16A3CYP3A4 | |
| SCHEMBL15521643 | 0.87 | KMT2A (0.67) | MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL29502532 | 0.86 | CISD1 (0.69) | ALDH1A1CISD1KDM4ESLC16A3CYP3A4 | |
| SCHEMBL12639966 | 0.86 | CISD1 (0.69) | ALDH1A1CISD1KDM4ESLC16A3CYP3A4 | |
| SCHEMBL12672953 | 0.86 | CISD1 (0.69) | ALDH1A1CISD1KDM4ESLC16A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | claimed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | claimed |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2017-12-21 | — | — | US | claimed |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-06-16 | — | — | US | claimed |
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2014-12-18 | — | — | US | claimed |
| EP-2804852-A2 | THERAPEUTIC COMPOUNDS | Regents Of The University Of Minnesota (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109972-A2 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-07-25 | — | — | WO | claimed |
| US-20060084176-A1 | Detection of uronium salts | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-04-20 | — | — | US | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-114507158-B | Pleuromutilin alpha-cyano cinnamic acid ester compounds with drug-resistant bacteria resisting activity and preparation method and application thereof | 广东医科大学附属医院 | 2023-04-28 | — | — | CN | disclosed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | disclosed |
| CN-114507158-A | Pleuromutilin alpha-cyano cinnamate compounds with drug-resistant bacterium resisting activity and preparation method and application thereof | 广东医科大学附属医院 | 2022-05-17 | — | — | CN | disclosed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-0335641-B1 | Organic nonlinear optical substance | TEIJIN LTD (JP) | 1994-01-05 | — | — | EP | disclosed |
| US-5196147-A | Optical crystals | TEIJIN LIMITED (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0335641-A2 | Organic nonlinear optical substance | TEIJIN LIMITED (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4284621-A | SUNSCREEN FOR SKIN | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
| US-4017486-A | Cationic alpha-cyano-p-dimethylaminocinnamoyl dyes and paper dyed therewith | AMERICAN CYANAMID COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | MEN1 28/4885MAPT 3241/4885KMT2A 3448/4885 |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | CA6, CA13, EPCAM | MEN1 2469/4885MAPT 2354/4885KMT2A 2760/4885 |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | MEN1 30/4885MAPT 3327/4885KMT2A 3288/4885 |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | CA6, CA13, EPCAM | MEN1 2469/4885MAPT 2354/4885KMT2A 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.